Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

GM-CSF-encoding Oncolytic Adenovirus CGTG-102

Known as: CGTG-102 
A recombinant, oncolytic serotype 5/3 capsid-modified adenovirus encoding the immunostimulatory cytokine granulocyte-macrophage colony-stimulating… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma
Despite originating from several different tissues, soft‐tissue sarcomas (STS) are often grouped together as they share… Expand
2014
2014
Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans
Sarcomas are a relatively rare cancer, but often incurable at the late metastatic stage. Oncolytic immunotherapy has gained… Expand
Highly Cited
2013
Highly Cited
2013
Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
Purpose: Multiple injections of oncolytic adenovirus could enhance immunologic response. In the first part of this article, the… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2012
2012
CGTG-102 (Ad5/3-D24-GMCSF), a novel oncolytic adenovirus, in patients with refractory solid tumors: Experience from an advanced therapy access program.
e13035 Background: Following preclinical testing CGTG-102, a 5/3 chimeric oncolytic adenovirus armed with human GMCSF, has been… Expand
2010
2010
American Society of Gene & Cell Therapy--13th Annual Meeting.
  • G. Romano
  • IDrugs : the investigational drugs journal
  • 2010
    • Corpus ID: 23535335
The American Society of Gene & Cell Therapy's 13th Annual Meeting, held in Washington, DC, included topics covering new… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE